[A26-74] Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Last updated 23.09.2026
Project no.:
A26-74
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
| Project no. | Title | Status |
|---|---|---|
| A22-11 | Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-12 | Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-88 | Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |